SCHEMBL19104694

SCHEMBL19104694

CC(C)(C)Cc1nc2cc(Cl)ccc2c(=O)[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.54
▸ POLB P06746 2/20 0.53
▸ KMT2A Q03164 3/20 0.52
▸ MAPT P10636 3/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ ATM Q13315 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ GAA P10253 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ ALOX12 P18054 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ TUBB4A P04350 2/20 0.48
▸ TUBB P07437 2/20 0.48
▸ TUBA3C P0DPH7 2/20 0.48
▸ TUBA1B P68363 2/20 0.48
▸ TUBA4A P68366 2/20 0.48
▸ TUBB4B P68371 2/20 0.48
▸ TUBB3 Q13509 2/20 0.48
▸ TUBB2A Q13885 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19104686 0.89 TUBB4A (0.61) LMNAPOLBKMT2AMAPTNPC1
SCHEMBL19104685 0.84 MAPT (0.47) LMNAPOLBKMT2AMAPTNPC1
SCHEMBL17298013 0.84 TNKS2 (0.62) LMNAPOLBKMT2AMAPTNPC1
SCHEMBL19104689 0.83 PARP14 (0.52) LMNAGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL6929589 0.82 KDM4E (0.65) LMNAPOLBKMT2AMAPTNPC1
SCHEMBL29900514 0.82 KDM4E (0.65) LMNAPOLBKMT2AMAPTNPC1
SCHEMBL28097943 0.81 POLB (0.56) LMNAPOLBKMT2AMAPTNPC1
SCHEMBL19116631 0.81 ALDH1A1 (0.56) LMNAKMT2AMAPTMEN1ATM
SCHEMBL28097938 0.80 PIM1 (0.57) LMNAPOLBKMT2AMAPTNPC1
SCHEMBL19104682 0.79 TNKS2 (0.69) LMNAPOLBKMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210363142-A1 AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute 2021-11-25 — — US disclosed
US-10988475-B2 Agonists of the apelin receptor and methods of use thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2021-04-27 — — US disclosed
US-20200354355-A1 AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2020-11-12 — — US disclosed
US-10570128-B2 Agonists of the apelin receptor and methods of use thereof Sanford Burnham Prebys Medical Discovery Institute (US) 2020-02-25 — — US disclosed
US-20170197958-A1 AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute 2017-07-13 — — US disclosed
US-20170197958-A1 AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF Sanford Burnham Prebys Medical Discovery Institute 2017-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210363142-A1 AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF APLNR, AGTR1, AGTR2 LMNA 2152/4885POLB 4265/4885KMT2A 3149/4885
US-10570128-B2 Agonists of the apelin receptor and methods of use thereof APLNR, AGTR1, AGTR2 LMNA 2152/4885POLB 4265/4885KMT2A 3149/4885
US-10988475-B2 Agonists of the apelin receptor and methods of use thereof APLNR, AGTR1, AGTR2 LMNA 2152/4885POLB 4265/4885KMT2A 3149/4885
US-20170197958-A1 AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF APLNR, AGTR1, AGTR2 LMNA 2152/4885POLB 4265/4885KMT2A 3149/4885
US-20200354355-A1 AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF APLNR, AGTR1, AGTR2 LMNA 2152/4885POLB 4265/4885KMT2A 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback